In vitro studies have confirmed that TAMs can contribute to the development of endocrine resistance in estrogen receptor-positive (ER+) breast cancer cells by prolonging the release of TNF-α and interleukin 6 both by themselves and by the cancer cells they affect. The gene discussed is ESR1; the disease is breast carcinoma.